CG Oncology, Inc. Common stock Net Asset Momentum
CG Oncology, Inc. Common stock net asset momentum. CG Oncology, Inc. Common stock (CGON) recorded a net asset momentum of 2.6% as of December 2025, with net assets of $752.60 Million USD. Net Asset Momentum measures the year-over-year percentage change in net assets (total assets minus total liabilities), indicating how rapidly the company is building or eroding its equity base. Explore CG Oncology, Inc. Common stock (CGON) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
YoY Momentum
Current Net Assets
Years of Data
Country
Net Asset Momentum of CG Oncology, Inc. Common stock (2021–2025)
Net asset momentum of CG Oncology, Inc. Common stock from 2021 to 2025. This chart tracks CG Oncology, Inc. Common stock's year-over-year net asset growth across 5 annual reporting periods from 2021 to 2025. The most recent momentum reading is +2.6%, with net assets of $752.60 Million USD as of December 2025. See CGON net assets for net asset value and shareholders' equity analysis.
CG Oncology, Inc. Common stock Net Asset Momentum by Year (2021–2025)
CG Oncology, Inc. Common stock net asset momentum by year from 2021 to 2025. The table below shows the complete annual net asset history for CG Oncology, Inc. Common stock from 2021 to 2025, covering 5 yearly periods. Each row includes total assets, total liabilities, net assets, and the year-over-year momentum figure for that period. For live market cap and overall valuation, see CGON company net worth.
| Year | Net Assets (USD) | Total Assets | Total Liabilities | YoY Momentum |
|---|---|---|---|---|
| 2025 | $752.60 Million | $791.59 Million | $38.99 Million | ▲ +2.6% |
| 2024 | $733.38 Million | $754.80 Million | $21.42 Million | ▲ +296.9% |
| 2023 | $184.79 Million | $199.30 Million | $14.51 Million | ▲ +47.6% |
| 2022 | $125.18 Million | $147.75 Million | $22.57 Million | ▲ +211.0% |
| 2021 | $40.25 Million | $58.69 Million | $18.44 Million | — |